Inhibitors of IAP

Details Inhibitors of IAP Inhibitors of IAP

2007-07-17

2007-07-17

Saeed, Kamal A. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S527000, C548S356100, C548S300100, C548S215000, C548S240000, C548S206000, C548S255000, C548S262600, C548S125000, C548S127000, C548S250000, C514S422000, C514S403000, C514S397000, C514S374000, C514S378000, C514S372000, C514S359000, C514S383000

Reexamination Certificate

active

11174784

ABSTRACT:
The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I:wherein X, Y, A, R1, R2, R3, R4, R4′, R5, R5′, R6and R6′ are as described herein.

REFERENCES:
patent: 4278793 (1981-07-01), Durckheimer et al.
patent: 4720484 (1988-01-01), Vincent et al.
patent: 5411942 (1995-05-01), Widmer et al.
patent: 5559209 (1996-09-01), Nishimoto
patent: 6472172 (2002-10-01), Deng et al.
patent: 6608026 (2003-08-01), Wang
patent: 6992063 (2006-01-01), Shi
patent: 7041784 (2006-05-01), Wang et al.
patent: 2002/0177557 (2002-11-01), Shi
patent: 2003/0157522 (2003-08-01), Boudreault et al.
patent: 2006/0052311 (2006-03-01), Sharma et al.
patent: WO92/01938 (1992-02-01), None
patent: WO 00/00823 (2000-01-01), None
patent: WO 00/39585 (2000-07-01), None
patent: WO 02/16402 (2002-02-01), None
patent: WO 02/16418 (2002-02-01), None
patent: WO 02/26775 (2002-04-01), None
patent: WO 02/30959 (2002-04-01), None
patent: WO 02/096930 (2002-12-01), None
patent: WO 03/010184 (2003-02-01), None
patent: WO 03/086470 (2003-10-01), None
patent: WO 2004/005248 (2004-01-01), None
patent: WO 2004/007529 (2004-01-01), None
patent: WO 2004/017991 (2004-03-01), None
patent: WO 2004/072641 (2004-08-01), None
patent: WO 2004/106371 (2004-12-01), None
patent: WO 2005/049853 (2005-06-01), None
patent: WO 2005/097791 (2005-10-01), None
patent: WO 2006/020060 (2006-02-01), None
Murray, et al. Journal of Biological Chemistry, 1984, 259, 17, p. 10722-10732.
U.S. Appl. No. 10/364,645, filed Jul. 2, 2003, Franklin, M. et al.
U.S. Appl. No. 10/983,495, filed Aug. 11, 2004, Fairbrother, W. et al.
Chai Jijie et al., “Structural and biochemical basis of apoptotic activation by SMAC/Diablo”Nature, London, GB:Nature Publishing Group vol. 406(6798):855-862 (Aug. 24, 2000).
Liu et al., “Structural Basis for Binding of Smac/DIABLO to the XIAP BIR3 Domain”Nature408:1004-1008 (Dec. 2000).
Arnt et al., “Synthetic Smac/DIABLO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ”J. Bio. Chem. 277(46):44236-44243 (Nov. 2002).
Fulda et al., “Smac Agonists Sensitize for Apo2L/TRAIL- or Anticancer Drug-Induced Apoptosis and Induce Regression of Malignant Glioma in Vivo”Nature Medicine8(8):808-815 (Aug. 2002).
Guo et al., “Ectopic Overexpression of Second Mitochondria-Derived Activator of Caspases (Smac/DIABLO) or Cotreatment with N-Terminus of Smac/DIABLO Peptide Potentiates Epothilone B Derivative-(BMS 247550) and Apo-2L/TRAIL-Induced Apoptosis”Blood99:3419-3426 (2002).
Vucic et al., “SMAC Negatively Regulates the Anti-apoptotic Activity of Melanoma Inhibitor of Apoptosis (ML-IAP)”The Journal of Biological Chemistry277:12275-12279 (2002).
Yang et al., “Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated smac peptide”Cancer Research63(4):831-837 (2003).

Affiliated with

Also associated with

Rating

Inhibitors of IAP does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of IAP, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of IAP will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3730365